Compare Quest Diagnostics Inc (DGX) vs Elastic NV (ESTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Elastic NV — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.48B), while Elastic NV trades at $95.65 (market cap $10.00B). The key difference: Quest Diagnostics Inc is far larger — about 2.5× Elastic NV's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Elastic NV pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Elastic NV for 10 Days on average.
| DGX | ESTC | |
|---|---|---|
Market Cap | $25.48B | $10.00B |
Volume | 941,866 | 1,610,337 |
Sector | Health | Technology |
52-Week High | $247.45 | $99.91 |
52-Week Low | $173.49 | $43.30 |
Typical Hold Time | 56 Days | 10 Days |
Enterprise Value | $31.23B | $9.14B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.
The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.
Elastic (ESTC) trades at $93.10, down 1.59% today but maintains strong technical momentum with a bullish moving average signal. The company shows robust revenue growth with Q2 2026 EPS beating expectations at $0.70 versus $0.584, and analyst consensus remains strongly positive with 22 buy ratings and no sell recommendations. Recent product launches including AI-powered metrics and serverless vector database enhancements demonstrate ongoing innovation.
The outlook remains favorable with projected revenue growth to $1.8B in 2026 and net income turning positive to $376M. Key risks include high valuation multiples and competitive pressures in the enterprise software space. The consensus price target of $79.50 suggests potential downside from current levels despite strong fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →
